🧬 Silencing Risk: Lepodisiran vs Lp(a)
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New hope for high Lp(a)! 💉 Lepodisiran, a long-acting siRNA, slashed Lp(a) by 94% with just 2 shots/year. 🔬 RNA precision meets cardiac prevention. 📉 Silent killer, silenced. #CardioTwitter #RNAtherapy #LipoproteinA
info_outline
💨 Breathing Battles: Navigating COPD Phenotypes
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🌬️🚶♂️ COPD comes in many forms! From chronic bronchitis 🪫 to emphysema 💨, frequent exacerbators 🚨, asthma-COPD overlap 🌪️, and eosinophilic type 🧫. Tailoring treatment to phenotype is key! #COPD #PrecisionMedicine #RespiratoryCare
info_outline
💊 TANDEM Triumph: Dual Power for LDL Cholesterol Reduction!
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚀 TANDEM Trial: Combining Obicetrapib & Ezetimibe for a powerful LDL reduction! 💊 ✅ -48.6% vs placebo, -27.9% vs Ezetimibe, -16.8% vs Obicetrapib 💪 Safe, effective, and oral! #Cardiology #LipidManagement #ASCVD
info_outline
Fungal Pharmacists, Fatty Liver, Future Frontiers 🧬🩸🍄
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
A gut fungus 🍄 (Fusarium foetens) secretes FF-C1 🧪, a metabolite that inhibits CerS6 and lowers ceramides 🩸—shielding mice from MASH 🛡️. Fungi aren’t just freeloaders—they may be our next therapeutic allies! 💊🧠 #Microbiome #LiverHealth #FungalTherapy #Science
info_outline
💪 Powerful Cholesterol Control: Obicetrapib in the Spotlight 🌟
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚀 Obicetrapib: A Breakthrough in LDL Lowering! 📉 Reduced LDL by 29.9% in high-risk patients (p<0.001) 💡 Promising adjunct to lipid-lowering therapy! #Cardiology #LipidManagement #HeartHealth 💓
info_outline
Fat Chance! 🔬🧬 Middle-Age Spread Starts at the Cellular Level
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Here’s a tweet with emojis based on the article: 🧬 Middle-age spread decoded! 🕰️ Visceral fat grows in midlife not from bigger cells—but new ones! 🎯 CP-A cells fire up fat formation via LIFR–STAT3 🔥 💊 Targeting them may halt metabolic disease before it starts. #Aging #Obesity #CellBiology #Metabolism 🧫 Would you like a version with a more humorous tone or one tailored for clinicians?
info_outline
🔍📊🛡️ Detect, Decode, Defend: A New Era in Coronary Risk Prediction
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New era in heart disease prediction! 🧬 + 🧪 + 🤖 = Meta-prediction model that beats PCE & QRISK3 📈 Detects hidden CAD risk in young, women & “low-risk” groups 🎯 Precision prevention just got personal. 🫀 Published in Nature Medicine #CardioTwitter #AI #Genomics #CAD
info_outline
Dr RR Baliga's Philosophical Discourses: Epicurus (Greece, 341–270 BCE) – Founder of Epicureanism
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Epicurus (341–270 BC) was an ancient Greek philosopher who founded Epicureanism, emphasizing the pursuit of a tranquil, happy life through ataraxia (freedom from fear) and aponia (absence of pain). His teachings combined atomism, ethics, and naturalistic theology, advocating simple living, friendship, and the rejection of superstition.
info_outline
Calcium Wars: Orbital Atherectomy vs. Balloon Angioplasty — The ECLIPSE Verdict ⚔️🧠💔
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨ECLIPSE Trial Results🚨 Orbital atherectomy 🌀 vs. balloon angioplasty 🎈 before stenting in severe coronary calcification 💔 🎯 No added benefit with atherectomy 🧠 Balloon-first + imaging = smart strategy 📊 Lancet 2025 | #CardioTwitter #InterventionalCardiology #ECLIPSETrial
info_outline
Genes 🧬, Journeys 🌍, and Hidden Hazards ⚡: Unlocking Health with Exposomics
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
“Your DNA 🧬 is just half the story — your exposome 🌍 writes the rest! From air 🌫️ to food 🍎 to stress 😰, exposomics unlocks the hidden drivers of health 🔍💥. Predict. Prevent. Prosper. 🚀 #Exposomics #PrecisionMedicine”
info_outline🫀 Cardiac CT Calcium Score: Key Insights 🔬📊
🔍 What is CAC?
✅ Measures calcified plaque in coronary arteries via cardiac CT 📸
✅ Higher CAC = Higher cardiovascular risk ⚠️
✅ Agatston Score: 0 (None) → >400 (Severe Atherosclerosis)
📊 Clinical Impact:
✅ Strong predictor of ASCVD events (MI, stroke, CHD death) 📉
✅ MESA Study: CAC >300 → 10-year CHD risk: 13-25%
✅ CAC = 0 → Low risk, even for some statin-eligible patients 🚀
🎯 Guidelines & Utility:
📢 Used for risk stratification in intermediate-risk patients (7.5%-20% ASCVD risk)
💊 Guides statin therapy decisions (CAC >100 = Strong statin recommendation)
⚖️ Not useful for symptomatic patients needing revascularization
🔬 Takeaway: CAC scoring enhances risk prediction, supports precision medicine, and helps optimize cardiovascular prevention strategies! 🚀